Checkpoint Therapeutics (NASDAQ:CKPT) versus Tyra Biosciences (NASDAQ:TYRA) Financial Comparison

Tyra Biosciences (NASDAQ:TYRA) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Profitability

This table compares Tyra Biosciences and Checkpoint Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-24.56%	-23.31%
Checkpoint Therapeutics	N/A	N/A	-659.07%

Volatility and Risk

Tyra Biosciences has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

Institutional & Insider Ownership

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are held by institutional investors. 15.4% of Tyra Biosciences shares are held by company insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Tyra Biosciences and Checkpoint Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$69.13 million	($1.61)	-8.85
Checkpoint Therapeutics	$47,000.00	3,678.06	-$51.85 million	($1.84)	-1.92

Checkpoint Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Tyra Biosciences and Checkpoint Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	0	0	5	0	3.00
Checkpoint Therapeutics	0	0	2	0	3.00

Tyra Biosciences presently has a consensus price target of $31.00, suggesting a potential upside of 117.54%. Checkpoint Therapeutics has a consensus price target of $13.50, suggesting a potential upside of 281.36%. Given Checkpoint Therapeutics’ higher probable upside, analysts clearly believe Checkpoint Therapeutics is more favorable than Tyra Biosciences.

Summary

Checkpoint Therapeutics beats Tyra Biosciences on 6 of the 11 factors compared between the two stocks.

About Tyra Biosciences

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.